Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026)

Regeneron Pharmaceuticals' Long-Term Investments history runs 18 years deep, the most recent figure standing at $9.8 billion for Q1 2026.

• In Q1 2026, Long-Term Investments rose 5.49% year-over-year to $9.8 billion; the TTM figure through Mar 2026 stood at $9.8 billion (up 5.49% YoY), while the FY2025 annual figure was $10.3 billion, up 15.29% from the prior year.
• Long-Term Investments was $9.8 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $10.3 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $10.3 billion in Q3 2025 to a low of $5.4 billion in Q4 2023.
• Historically, Long-Term Investments has averaged $7.7 billion across 5 years, with a median of $7.1 billion in 2022.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments jumped 99.9% in 2022, then retreated 18.13% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $6.6 billion in 2022, then retreated by 18.13% to $5.4 billion in 2023, then soared by 64.92% to $8.9 billion in 2024, then gained by 15.29% to $10.3 billion in 2025, then retreated by 4.63% to $9.8 billion in 2026.
• The last three Long-Term Investments figures came in at $9.8 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.3 billion (Q3 2025), per Business Quant data.